Trial Profile
Combination anti-paratuberculosis therapy with rifabutin, clarithromycin and clofazimine for Crohn's disease: a three year prospective, randomised, placebo-controlled, multicentre study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Clarithromycin/clofazimine/rifabutin (Primary)
- Indications Bacterial infections; Crohn's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 05 Nov 2010 New trial record.